Medication related osteonecrosis of the jaw

BetterLife (OTCQB:BETRD) Launches Website Emphasizing 3 Potentially Ground Breaking Treatments

Retrieved on: 
Tuesday, July 14, 2020
Musculoskeletal system, Organ systems, Skeletal system, Osteonecrosis, Bone metastasis, Bone, Medication related osteonecrosis of the jaw, Metástasis, Metastatic breast cancer, RANKL

The new website, http://www.blifetherapeutics.com , provides visitors with an overview of the Companys treatment development pipeline, including information on the trial Phases for each of the treatments.

Key Points: 
  • The new website, http://www.blifetherapeutics.com , provides visitors with an overview of the Companys treatment development pipeline, including information on the trial Phases for each of the treatments.
  • Not only did IFNa2b help patients' immune systems clear thecoronavirusfaster, it also seemed to reduce certain inflammatory proteins linked to severe COVID-19 complications.
  • AP-002 is unique in that it has both anti-bone resorption and direct anti-tumour cell killing activity.
  • Bone metastases often result in severe pain, spinal cord compression and cancer-induced bone fractures, collectively referred to as skeletal related events (SREs).

Global Osteoporosis Drugs Market by Route of Administration, Drug Class and Region - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 6, 2020
Health, Pharmaceutical, Hormones, Organ systems, RTT, Progonadotropins, Bisphosphonate, Selective estrogen receptor modulators, Phenols, Osteoporosis, Chemical compounds, Phosphonate, Medication related osteonecrosis of the jaw, Aromatase inhibitor

The "Global Osteoporosis Drugs Market By Route of Administration, By Drug Class, By Region, Industry Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Osteoporosis Drugs Market By Route of Administration, By Drug Class, By Region, Industry Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Osteoporosis Drugs Market size is expected to reach $10.9 billion by 2026, rising at a market growth of 4.4% CAGR during the forecast period.
  • Many of the drugs on the market include selective estrogen inhibitor modulator (SERM) bisphosphonates, parathyroid hormone treatment, calcitonin, and RANK ligand inhibitors.
  • Bisphosphonates are a type of drug used to reduce deterioration of the bone structure and to treat osteoporosis and related diseases.

Brentwood Periodontist uses holistic alternative to bone grafting

Retrieved on: 
Tuesday, June 23, 2020
Medical specialties, Medicine, Transplantation medicine, Dentistry, Oral and maxillofacial surgery, Oral surgery, Bone grafting, Dental implant, Human tooth, Graft, Dentin, Medication related osteonecrosis of the jaw

BRENTWOOD LOS ANGELES, Calif., June 23, 2020 /PRNewswire/ -- Autogenous Dentin Grafting has become a viable solution for patients seeking a holistic alternative to conventional bone grafting.

Key Points: 
  • BRENTWOOD LOS ANGELES, Calif., June 23, 2020 /PRNewswire/ -- Autogenous Dentin Grafting has become a viable solution for patients seeking a holistic alternative to conventional bone grafting.
  • Dental grafting commonly utilizes bone tissue taken from humans or animals to regenerate bone tissue and restore density in the jaw.
  • Dental grafting procedures restore patients' bone density to its previous, optimal form prior to tooth loss.
  • The graft successfully regenerates the bone in 6 weeks versus 12 and restores the bone density needed to support dental implants.

Board-Certified Periodontist Makes Full Mouth Dental Implants Possible for Severe Bone Loss Patients in West Covina, CA

Retrieved on: 
Friday, June 19, 2020
Dentistry, Medical specialties, Medicine, Oral surgery, Restorative dentistry, Prosthodontology, Dental equipment, Dental implant, Bone grafting, All-on-4, Human tooth, Medication related osteonecrosis of the jaw

Thanks to the revolutionary All-on-4 full mouth dental implant solution , even patients experiencing bone loss in their jaw can receive a full mouth of new teeth in just one day, while preventing further bone loss.

Key Points: 
  • Thanks to the revolutionary All-on-4 full mouth dental implant solution , even patients experiencing bone loss in their jaw can receive a full mouth of new teeth in just one day, while preventing further bone loss.
  • Those with missing teeth or bone loss in West Covina, CA are invited to experience the benefits of All-on-4 at Dr. Kim's practice.
  • With All-on-4 full mouth dental implants, Dr. Kim can maximize the use of available bone by strategically placing just four dental implants into the jaw.
  • This often means that patients who have extensive bone loss in their mouth can still receive dental implants without undergoing the hassle of a bone graft.

Pfenex Announces U.S. Commercial Launch of Teriparatide Injection

Retrieved on: 
Friday, June 12, 2020
Eli Lilly and Company, Teriparatide, Medication related osteonecrosis of the jaw, Medical specialties, RTT

Teriparatide Injection is the first teriparatide product since Forteo (teriparatide injection)1-3 approved for this use.

Key Points: 
  • Teriparatide Injection is the first teriparatide product since Forteo (teriparatide injection)1-3 approved for this use.
  • We are pleased to announce the availability of Teriparatide Injectionin pharmacies - the first new FDA-approved teriparatide, which provides an alternative to Forteo,said Pfenex CEO Eef Schimmelpennink.
  • (Prescribing Information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b007339-dd0d-f...)
    As part of drug testing, teriparatide, the active ingredient in Teriparatide Injection, was given to rats for a significant part of their lifetime.
  • Pfenexs lead product is Teriparatide Injection (previously referred to as PF708 and Bonsity), a therapeutic equivalent candidate to Forteo (teriparatide injection).

FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant

Retrieved on: 
Monday, April 27, 2020
Research, Medical devices, FDA, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Science, Branches of biology, Health, Musculoskeletal system, Osteonecrosis, Anatomical pathology, Bone healing, Physiology, Medication related osteonecrosis of the jaw, Investigational New Drug, Bone, Food and Drug Administration, Osteochondritis dissecans, Carmell’s PBM Technology Platform, Carmell Therapeutics

In December, U.S. Food and Drug Administration (FDA) cleared the companys Investigational New Drug application (IND) for the Companys first product, a Bone Healing Accelerant (BHA).

Key Points: 
  • In December, U.S. Food and Drug Administration (FDA) cleared the companys Investigational New Drug application (IND) for the Companys first product, a Bone Healing Accelerant (BHA).
  • The FDA accepted the data and the overall study design from the companys double-arm, multicenter, Phase II clinical trial of Bone Healing Accelerant in open tibia fractures.
  • Carmell currently has two PBM products in development a Bone Healing Accelerant and a Tissue Healing Accelerant.
  • Carmell Therapeutics (Carmell) is addressing the burden of bone and tissue healing with its proprietary Plasma-based Bioactive Materials (PBM) technology, designed to improve patient outcomes and reduce health care costs.

Q BioMed Launches Non-opioid Treatment for Metastatic Bone Pain

Retrieved on: 
Thursday, February 13, 2020
Musculoskeletal system, Neoplasms, RTT, Strontium-89, Bone metastasis, Infectious causes of cancer, Oncology, Bone tumor, Prostate cancer, Metástasis, Medication related osteonecrosis of the jaw, Cancer

Under its distribution relationship with Jubilant Radiopharma, Q BioMed has the capability to reach patients in all 50 states.

Key Points: 
  • Under its distribution relationship with Jubilant Radiopharma, Q BioMed has the capability to reach patients in all 50 states.
  • We look forward to being able to help serve the unmet needs of the millions of patients suffering fromdebilitating bone pain associated with metastatic cancer.
  • Q BioMed is also planning further research for Strontium89 for potential label extension into therapeutic use for survival benefit in metastatic bone cancer through a Phase IV study.
  • Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.

Orthofix Announces FDA Approval of STIM onTrack 2.1 Mobile App for Bone Growth Stimulators

Retrieved on: 
Thursday, February 13, 2020
Data management, Medical devices, FDA, Health, Technology, Managed care, Human sexuality, Sexuality, Erotic electrostimulation, Masturbation, Sexual fetishism, Medical device, Mobile app, Medication related osteonecrosis of the jaw, Bone Growth Stimulators, Orthofix

(NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the U.S. Food and Drug Administration (FDA) approval of the STIM onTrack mobile app version 2.1 for use with the Companys bone growth stimulators.

Key Points: 
  • (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the U.S. Food and Drug Administration (FDA) approval of the STIM onTrack mobile app version 2.1 for use with the Companys bone growth stimulators.
  • View the full release here: https://www.businesswire.com/news/home/20200213005257/en/
    STIM onTrack 2.1 Mobile App for Bone Growth Stimulators (Photo: Business Wire)
    The STIM onTrack technology works with the Orthofix Bone Growth Therapy devices.
  • The mobile device app is an accessory designed to help patients adhere to their prescriptions and improve their clinical outcomes.
  • The STIM onTrack mobile app version 2.1 is an upgrade of the original STIM onTrack mobile app that was first introduced in 2017.

Bioventus Updates US Label for EXOGEN® Ultrasound Bone Healing System

Retrieved on: 
Monday, February 10, 2020
Biotechnology, Surgery, Medical devices, Health, Pharmaceutical, Musculoskeletal system, Branches of biology, Bone fractures, Anatomy, Exogen, Nonunion, Bone fracture, Low-intensity pulsed ultrasound, Lipus, Bone healing, Bone, Medication related osteonecrosis of the jaw

Bioventus , a global leader in orthobiologic solutions, has updated the indications for use for its EXOGEN Ultrasound Bone Healing System .

Key Points: 
  • Bioventus , a global leader in orthobiologic solutions, has updated the indications for use for its EXOGEN Ultrasound Bone Healing System .
  • EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the bodys natural bone healing process and promote fracture healing.
  • View the full release here: https://www.businesswire.com/news/home/20200210005036/en/
    EXOGEN Ultrasound Bone Healing System from Bioventus (Photo: Business Wire)
    The updated label now prominently features indications for using EXOGEN as an adjunctive non-invasive treatment of established nonunions in patients:
    This label update underscores important usage scenarios where fracture management protocol may have limited consideration.
  • Patients with comorbidities such as osteoporosis and bone infection can benefit from use of EXOGEN by helping to progress fracture healing and resolve nonunion.

Promising New Treatment Plan for Jaw Osteonecrosis

Retrieved on: 
Tuesday, December 10, 2019
Dentistry, Osteonecrosis, Health, Medical specialties, Medication related osteonecrosis of the jaw, Osteonecrosis of the jaw, Bisphosphonate, Dental implant, Avascular necrosis, C-terminal telopeptide

One such complication is bone tissue death, known as osteonecrosis, which can result when patients take drugs, such as bisphosphonates, for bone diseases.

Key Points: 
  • One such complication is bone tissue death, known as osteonecrosis, which can result when patients take drugs, such as bisphosphonates, for bone diseases.
  • However, a recent case study in the Journal of Oral Implantology describes the successful treatment of a patient with osteonecrosis by using a new regimen.
  • The clinicians detailed numerous improvements that were seen throughout the treatment period as well as 6 months after the treatment.
  • Full text of the article "Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review," Journal of Oral Implantology, is available at https://doi.org/10.1563/aaid-joi-D-19-00040 .